Search Result

Results for "

Cannabinoid Receptor Agonist

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Cannabinoid Receptor (95) 5-HT Receptor (1) Androgen Receptor (1) ANGPTL (1) Apoptosis (1) Caspase (1) CETP (1) Cholinesterase (ChE) (1) Cytochrome P450 (1) Drug Intermediate (1) Drug Isomer (1) Endogenous Metabolite (9) Environmental Pollutants (2) FAAH (1) Fatty Acid Synthase (FASN) (1) HIF/HIF Prolyl-Hydroxylase (2) Interleukin Related (3) Isotope-Labeled Compounds (2) MHC (1) PDK-1 (1) PERK (1) Potassium Channel (1) Reactive Oxygen Species (ROS) (1) Reference Standards (4) Sigma Receptor (1) TNF Receptor (2) TRP Channel (4) VEGFR (1) α-synuclein (1)
By Research Areas:	Cancer (12) Cardiovascular Disease (2) Endocrinology (2) Inflammation/Immunology (22) Metabolic Disease (14) Neurological Disease (64)
Click Chemistry:	Azide (1)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: Cannabinoid Receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-153169

6PPD-Q 5+ Cited Publications 6PPD-Quinone	α-synuclein Environmental Pollutants	Others
6PPD-Q (6PPD-Quinone) is an environmental pollutant that can be detected in human urine and is widely present in the environment. 6PPD-Q targets and binds to CNR2, CNR1, AA2AR, LCAT, and TRPA1, with CNR2 exhibiting the highest binding affinity, potentially acting as a CNR2 receptor agonist to activate cannabinoid receptors. 6PPD-Q induces intestinal inflammation and barrier damage by disrupting mitochondrial function, reducing neuronal glycolysis metabolites and TCA cycle intermediates, and exacerbating α-synuclein (α-syn) aggregation. 6PPD-Q is applicable in research on environmental toxicology, neurodegenerative diseases, and inflammation-related disorders .

HY-15443

AM251 Maximum Cited Publications 23 Publications Verification	Cannabinoid Receptor	Neurological Disease
AM251 is a selective cannabinoid 1 (CB1) receptor antagonist with an IC₅₀ of 8 nM. AM251 also acts as a potent GPR55 agonist with an EC₅₀ of 39 nM .

HY-110004

ACEA Arachidonyl-2-chloroethylamide	Cannabinoid Receptor	Others
ACEA (short for arachidonyl-2'-chloroacetamide) is a synthetic organic compound that acts as an agonist of the cannabinoid receptor CB1. It is a chemical that affects the endocannabinoid system in the body, which regulates various physiological processes such as appetite, pain perception, mood, and memory .

HY-15451

MDA 19 2 Publications Verification BZO-HEXOXIZID	Cannabinoid Receptor	Neurological Disease
MDA 19 is a potent and selective agonist of human cannabinoid receptor 2 (CB2), with a K_i of 43.3 nM. MDA 19 has antiallodynic effects in a rat model of neuropathic pain and does not affect rat locomotor activity .

HY-10013

Taranabant 2 Publications Verification MK-0364	Cannabinoid Receptor	Metabolic Disease
Taranabant is a highly potent and selective cannabinoid 1 (CB1) receptor inverse agonist that inhibits the binding and functional activity of various agonists, with a binding K_i of 0.13 nM for the human CB1R in vitro.

HY-103325

JTE-907	Cannabinoid Receptor TRP Channel Interleukin Related ANGPTL VEGFR	Metabolic Disease Inflammation/Immunology
JTE-907 is a selective and orally active cannabinoid CB2 receptor inverse agonist and exerts anti-inflammatory effects. JTE-907 upregulates IL-6, MCP-1, IL-1β, VEGF, ANGPTL4, and TRPV1 in mature adipocytes. JTE-907 downregulates CB1, MCP-1, and IL-1β in preadipocytes. JTE-907 inhibits ear swelling in mice. JTE-907 reverses the protective effects of CB2 agonists and Anandamide (HY-10863) against cytokine-evoked colonic mucosal damage. JTE-907 can be used for the research of allergic dermatitis, obesity, and colitis .

HY-111110

Olorinab 2 Publications Verification APD 371	Cannabinoid Receptor	Neurological Disease
Olorinab (APD 371) is a highly potent, selective and fully efficacious cannabinoid receptor type 2 (CB₂) agonist, with an EC₅₀ of 6.2 nM for hCB₂.

HY-14167

GW842166X	Cannabinoid Receptor	Neurological Disease Inflammation/Immunology
GW842166X is a potent and selective cannabinoid receptor 2 (CB2) agonist with IC₅₀ values of 63 and 91 nM for human and rat CB2, respectively.

HY-100488

Bay 59-3074	Cannabinoid Receptor	Cancer
Bay 59-3074 is a selective cannabinoid CB₁/CB₂ receptor partial agonist with K_i values of 48.3 and 45.5 nM at human CB₁ and CB₂ receptors, respectively. Bay 59-3074 has analgesic properties .

HY-120423

AM-6538	Cannabinoid Receptor	Neurological Disease
AM6538 is a long-acting, high affinity and pseudo-irreversible cannabinoid (CB) antagonist. AM6538 is a structural analog of rimonabant. AM6538 can be effectively used to evaluate the apparent efficacy of cannabinoid full and partial agonists. AM6538 may be useful in future studies that require temporary reductions in cannabinoid receptor availability . AM-6538 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-110028

Leelamine hydrochloride	Cannabinoid Receptor Fatty Acid Synthase (FASN) Androgen Receptor	Endocrinology Cancer
Leelamine hydrochloride is a tricyclic diterpene molecule that is extracted from the bark of pine trees . Leelamine hydrochloride is a cannabinoid receptor type 1 (CB1) agonist and a inhibitor of SREBP1-regulated fatty acid/lipid synthesis in prostate cancer cells that is not affected by androgen receptor status. Leelamine hydrochloride suppresses transcriptional activity of androgen receptor, which is known to regulate fatty acid synthesis ^[2,3].

HY-112340

CB1 antagonist 4	Cannabinoid Receptor	Neurological Disease Metabolic Disease
CB1 antagonist 4 (compound 8) is a selective cannabinoid receptor 1 (CB1) inverse agonist with an IC₅₀ of 8.5 nM for human CB1. CB1 antagonist 4 shows selective for CB1 over CB2 receptors (IC₅₀ of 604.9 nM). CB1 antagonist 4 inhibits GTP binding to CB1-overexpressing cell membranes with an EC₅₀ of 18.5 nM .

HY-W005629

Leelamine	Environmental Pollutants Cannabinoid Receptor PDK-1	Metabolic Disease Cancer
Leelamine is an orally active pyruvate dehydrogenase kinase (PDK) inhibitor with an IC₅₀ value of 9.5 μM, showing a blood glucose lowering effect in the diabetic mouse. Leelamine is also a weak agonist of cannabinoid receptors CB1 and CB2. Leelamine decreases mitotic activity, prostate-specific antigen expression and induces Apoptosis to cell death in cancer cells .

HY-116649

CB1 antagonist 2 AM4113	Cannabinoid Receptor	Neurological Disease Metabolic Disease
CB1 antagonist 2 (AM4113) is an orally active cannabinoid receptor type 1 (CB1R) antagonist. CB1 antagonist 2 suppresses appetite, reduces body weight, and blocks addictive behaviors such as heroin addiction, without causing adverse effects like nausea and depression that are associated with traditional CB1 inverse agonists. CB1 antagonist 2 can be used in studies related to obesity and opioid addiction .

HY-122153

VSN-16	Cannabinoid Receptor	Cardiovascular Disease Inflammation/Immunology
VSN-16 is a **cannabinoid receptor** agonist with vasodilatory activity. VSN-16 can be used for the study of multiple sclerosis .

HY-110036

GW-405833 L768242	Cannabinoid Receptor Endogenous Metabolite HIF/HIF Prolyl-Hydroxylase TNF Receptor Interleukin Related	Neurological Disease Inflammation/Immunology
GW-405833 (L768242) is a potent, selective cannabinoid receptor 2 (CB₂) agonist. GW405833 has EC₅₀ and K_i values of 0.65 nM and 3.92 nM for CB₂, and EC₅₀ and K_i values of 16.1 μM and 4772 nM for CB₁. GW-405833 also exhibits non-competitive CB₁ antagonist, exerting its analgesic and and anti-inflammatory effect through a CB₁ receptor (rather than CB₂) dependent mechanism. GW-405833 can significantly inhibit the production of cAMP stimulated by Forskolin (HY-15371). GW405833 inhibits glycolysis by down-regulating HIF-1α, thereby alleviating acute liver failure (ALF) .

HY-10013A

Taranabant racemate MK-0364 racemate	Cannabinoid Receptor	Neurological Disease
Taranabant racemate (MK-0364 racemate) is an antagonist and/or inverse agonist of the *Cannabinoid-1* (CB1) *receptor* extracted from patent WO 2004048317 A1 .

HY-132217

CB2 receptor agonist 2	Cannabinoid Receptor	Neurological Disease
CB2 receptor agonist 2 is a potent and selective agonist for the CB2 (cannabinoid type 2) receptor with a K_i of 8.5 nM. CB2 receptor agonist 2 has high affinity and selectivity for CB2 .

HY-113070

Dihomo-γ-Linolenoyl Ethanolamide	Cannabinoid Receptor Endogenous Metabolite	Neurological Disease
Dihomo-γ-Linolenoyl Ethanolamide, an endocannabinoid, is a cannabinoid (CB) receptor agonist with K_is of 857 nM and 598 nM for human recombinant CB1 and CB2 receptors, respectively .

HY-110050

GP1a	Cannabinoid Receptor	Neurological Disease Inflammation/Immunology
GP1a is a potent agonist of cannabinoid receptor 2 (CB2). Gp1a is beneficial to skin wound healing. GP1a inhibits inflammation and fibrogenesis while promoting re-epithelialization .

HY-119104

AZD1940 1 Publications Verification	Cannabinoid Receptor	Neurological Disease
AZD1940 is an orally active, high affinity **cannabinoid CB1/CB2 receptor** agonist with pK_i values of 7.93 and 9.06 for human CB1R and CB2R, respectively. AZD1940 shows a robust analgesia action .

HY-P1091

Hemopressin (human, mouse)	Cannabinoid Receptor	Neurological Disease
Hemopressin is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin exerts antinociceptive action in inflammatory pain models .

HY-177425

AM11542	Cannabinoid Receptor	Metabolic Disease
AM11542 is a cannabinoid receptor 1 (CB1) agonist with a human CB1 K_i of 0.11 nM. AM11542 stabilizes the active conformational state of the CB1 receptor. AM11542 can be used for the research of obesity .

HY-150029

CB1/2 agonist 3	Cannabinoid Receptor	Neurological Disease
CB1/2 agonist 3 (compound 52), a potent non-selective cannabinoid ligand, is a CB1/CB2 (cannabinoid receptor) competitive agonist. CB1/2 agonist 3 acts on hCB1 and hCB2 with K_i values of 5.9 nM and 3.5 nM, respectively .

HY-12095

CB1 inverse agonist 2	Cannabinoid Receptor	Neurological Disease
CB1 inverse agonist 2 is an orally active inverse agonist of Cannabinoid Receptor CB1. CB1 inverse agonist 2 effectively inhibits CP55940-induced hypothermia and anorexia in mice model .

HY-110003

Arachidonylcyclopropylamide 2 Publications Verification ACPA	Cannabinoid Receptor	Neurological Disease
Arachidonylcyclopropylamide (ACPA) is a potent and selective CB1 receptors agonist. Arachidonylcyclopropylamide inhibits forskolin-stimulated cAMP production in CHO cells transfected with human cannabinoid CB1 receptors (IC₅₀=2 nM) .

HY-124283A

LEI-101	Cannabinoid Receptor	Neurological Disease
LEI-101 is a potent, selective, and orally bioavailable **cannabinoid CB2 receptor** agonist, with a pEC₅₀ of 8 for hCB2, and a pK_i of less than 4 for hERG. LEI-101 is ~100-fold more potent in binding to CB2 receptors than to CB1 receptors .

HY-P1090

Hemopressin(rat)	Cannabinoid Receptor	Neurological Disease
Hemopressin(rat) is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin(rat) is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin(rat) exerts antinociceptive action in inflammatory pain models .

HY-145153

S-777469	Cannabinoid Receptor	Neurological Disease
S-777469 is a selective and orally available cannabinoid type 2 receptor (CB2) agonist with a K_i of 36 nM. S-777469 significantly suppresses compound 48/80-induced scratching behavior in mice in a dose-dependent manner. S-777469 produces its antipruritic effects by inhibiting itch signal transmission through CB2 agonism .

HY-12761

A-836339	Cannabinoid Receptor	Cardiovascular Disease Others Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
A-836339 is a selective CB2 receptor agonist, with Ki values of 0.4 nM and 0.8 nM in humans and rats, respectively. A-836339 exhibits multiple effects such as analgesia, gastric protection, anti-inflammation, and antioxidant activity. A-836339 produces antinociceptive and analgesic activities by activating CB2 receptors in the dorsal root ganglia and spinal cord. A-836339 can also exert gastric protective effects through anti-inflammatory mechanisms (reducing TNF-α and IL-1β) and antioxidant mechanisms (enhancing the activities of CAT and SOD, and reducing H₂O₂). Radioactively labeled A-836339 can serve as a CB2-specific radioligand for autoradiography and PET imaging. A-836339 can be used in research on inflammatory pain, neuropathic pain, gastric ulcers, cerebral ischemia, etc .

HY-W013788

2-Palmitoylglycerol 2-Palm-Gl	Cannabinoid Receptor	Neurological Disease
2-Palmitoylglycerol (2-Palm-Gl), an congener of 2-arachidonoylglycerol (2-AG), is a modest cannabinoid receptor CB1 agonist. 2-Palmitoylglycerol also may be an endogenous ligand for GPR119 .

HY-121541

CB-25	Cannabinoid Receptor	Cancer
CB-25 is a ligand of CB1 **cannabinoid receptors*, acting as a partial agonist*. CB-25 enhances Forskolin (HY-15371)-induced cAMP formation in cancer cells but not hCB1-CHO cells .

HY-14900

Tedalinab 1 Publications Verification GRC-10693	Cannabinoid Receptor	Inflammation/Immunology
Tedalinab (GRC-10693) is a potent, orally active, and selective cannabinoid receptor 2 (CB2) agonist. Tedalinab has >4700-fold functional selectivity for CB2 over CB1. Tedalinab has potential for neuropathic pain and osteoarthritis treatment .

HY-124089

Eicosapentaenoyl ethanolamide	Cannabinoid Receptor	Metabolic Disease
Eicosapentaenoyl ethanolamide, an omega-3 fatty acid, is one of N-acylethanolamines (NAEs). Eicosapentaenoyl ethanolamide is **cannabinoid CB1/CB2 receptor** agonist. Eicosapentaenoyl ethanolamide acts as a metabolic signal. Eicosapentaenoyl ethanolamide inhibits dietary restriction (DR)-induced lifespan extension in wild type animals and suppresses lifespan extension in a TOR pathway mutant .

HY-152251

CB2R/FAAH modulator-1	Cannabinoid Receptor FAAH	Inflammation/Immunology
CB2R/FAAH modulator-1 is a cannabinoid type 2 receptor (CB2R) full agonist with K_is of 14.8 nM and 241.3 nM for CB2R and CB1R, respectively. CB2R/FAAH modulator-1 is a fatty acid amide hydrolase (FAAH) inhibitor with an IC₅₀ of 4 μM. CB2R/FAAH modulator-1 decreases pro-inflammatory and increases anti-inflammatory cytokines production .

HY-110014

Noladin ether	Cannabinoid Receptor	Neurological Disease
Noladin ether is a potent and selective agonist of **cannabinoid CB₁ receptor, with a K_i** of 21.2 nM. Noladin ether can cause hypothermia, intestinal immobility, and mild antinociception .

HY-110065

SER-601	Cannabinoid Receptor	Neurological Disease
SER-601 is a potent and selective peripheral cannabinoid (CB2) receptor agonist with a K_i of 6.3 nM. SER-601 has analgesic and antidiabetic properties and can be used for relevant research .

HY-110194

Virodhamine TFA	Endogenous Metabolite Cannabinoid Receptor	Neurological Disease
Virodhamine TFA is an endocannabinoid, it regulates neurotransmission by activating the cannabinoid (CB) receptors. Virodhamine is an antagonist of CB1 receptor and an agonist of CB2 receptor. Virodhamine TFA induces megakaryocytic differentiation by triggering MAPK signaling and ROS production. Virodhamine TFA can be used for the research of various neurological disorders such as Alzheimer's and Parkinson's diseases .

HY-152576

CB2R agonist 1	Cannabinoid Receptor	Inflammation/Immunology
CB2R agonist 1 is a selective ligand of cannabinoid receptor subtype 2 (CB2R) with an EC₅₀ value of 0.56 µM. CB2R agonist 1 has high affinity and excellent selectivity for human CB2R and CB1R respectively. CB2R agonist 1 regulates the production of pro-inflammatory cytokines and anti-inflammatory cytokines and play an immunomodulatory role .

HY-110036A

GW405833 hydrochloride L768242 hydrochloride	Cannabinoid Receptor Endogenous Metabolite HIF/HIF Prolyl-Hydroxylase TNF Receptor Interleukin Related	Neurological Disease Inflammation/Immunology
GW405833 (L768242) hydrochloride is a potent, selective cannabinoid receptor 2 (CB₂) agonist. GW405833 has EC₅₀ and K_i values of 0.65 nM and 3.92 nM for CB₂, and EC₅₀ and K_i values of 16.1 μM and 4772 nM for CB₁. GW405833 hydrochloride also exhibits non-competitive CB₁ antagonist, exerting its analgesic effect through a CB₁ receptor (rather than CB₂) dependent mechanism. GW405833 hydrochloride can significantly inhibit the production of cAMP stimulated by Forskolin (HY-15371). GW405833 hydrochloride inhibits glycolysis by down-regulating HIF-1α, thereby alleviating acute liver failure (ALF) .

HY-171883

BI-5756	Cannabinoid Receptor CETP MHC	Metabolic Disease Inflammation/Immunology Cancer
BI-5756 is a CETP inhibitor and cannabinoid receptor 1 (CB1) agonist. BI-5756 can significantly increase HDL-C levels and reduce LDL-C levels. BI-5756 can also enhance the function of regulatory T cells while maintaining T cell-mediated anti-tumor activity. BI-5756 can directly inhibit the growth of tumor cells and upregulate the expression of MHC I, MHC II, and CD80 on tumor cells. BI-5756 has a protective effect in graft-versus-host disease models. BI-5756 can be used in research on tumors, graft-versus-host disease, and metabolic diseases .

HY-128040

Virodhamine hydrochloride	Endogenous Metabolite Cannabinoid Receptor	Neurological Disease
Virodhamine (hydrochloride) is a cannabinoid CB1 receptor partial agonist and cannabinoid CB2 receptor full agonist .

HY-150067

CB1R antagonist 1	Cannabinoid Receptor	Metabolic Disease
CB1R Allosteric modulator 5, a selective cannabinoid-1 receptor (CB1R) inverse agonist with an IC₅₀ value of 4.2 μM and EC₅₀ value of ＞10 μM. CB1R Allosteric modulator 5 can be used for the research of metabolic and obesity .

HY-168734

CB2 receptor agonist 9	Cannabinoid Receptor	Inflammation/Immunology
CB2 receptor agonist 9 (Compound 33) is an orally active agonist for cannabinoid receptor 2 (CB2 receptor) with an EC₅₀ of 16.2 nM. CB2 receptor agonist 9 inhibits the expression of TNF-α, IL-1β and IL-6, exhibits anti-inflammatory efficacy in DDS (HY-116282)-induced mouse acute colitis model .

HY-168997

CB1R agonist 1	Cannabinoid Receptor	Neurological Disease Inflammation/Immunology
CB1R agonist 1 is a potent, CNS-penetrant, and selective Cannabinoid-1 receptor (CB1R) agonist with a Ki of 0.95 nM, modulating G_i/o signaling. CB1R agonist 1 exhibits high selectivity over CB2R and other off-target GPCRs, including GPR55, GPR18, and GPR119. CB1R agonist 1 induces analgesia and hypothermia, and potentiates opioid analgesia in mice. CB1R agonist 1 can be used for the research of pain .

HY-100778

SMM-189	Cannabinoid Receptor	Neurological Disease
SMM-189 is a potent and selective cannabinoid receptor 2 (CB2) inverse agonist. SMM-189 plays an important role in neurodegenerative disorders and traumatic brain injury research .

HY-173083

MDA7	Cannabinoid Receptor	Neurological Disease
MDA7 is the selective agonist for cannabinoid receptor 2 with EC₅₀ of 128 nM and 67.4 nM in human CB2 receptor and rat CB2 receptor. MDA7 exhibits good affinity to human CB2 receptor and rat CB2 receptor with K_i of 422 nM and 238 nM. MDA7 exhibits analgesic activity in rats models .

HY-W751734

HU 433	Cannabinoid Receptor	Others Neurological Disease Inflammation/Immunology
HU 433 is a synthetic cannabinoid CB2 receptor agonist and is the enantiomer of HU 308 (HY-161510). HU 433 exerts its anti-inflammatory and neuroprotective effects by binding to CB2 receptors. HU 433 can be used in the study of neuroinflammation and retinal diseases .

HY-175481

CB2R agonist 4	Cannabinoid Receptor Apoptosis Reactive Oxygen Species (ROS)	Cancer
CB2R agonist 4 is a cannabinoid receptor 2 (CB2R) agonist with an EC₅₀ value of 6.9 μM. CB2R agonist 4 can induce cell apoptosis, ROS production and protein misfolding. CB2R agonist 4 shows cytotoxicity to a panel of tumor cell lines. CB2R agonist 4 can be used for the research of cancer .

HY-149644

CB2R agonist 3	Cannabinoid Receptor	Inflammation/Immunology
CB2R agonist 3 is an agonist of **cannabinoid receptor 2 (CB2R), with EC₅₀** of 0.37μM that plays an important role in immune system .

Cat. No.	Product Name	Target	Research Area

HY-P1091

Hemopressin (human, mouse)	Cannabinoid Receptor	Neurological Disease
Hemopressin is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin exerts antinociceptive action in inflammatory pain models .

HY-P1090

Hemopressin(rat)	Cannabinoid Receptor	Neurological Disease
Hemopressin(rat) is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin(rat) is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin(rat) exerts antinociceptive action in inflammatory pain models .

HY-P1397

RVD-Hpα	Cannabinoid Receptor	Neurological Disease
RVD-Hpα, an α-hemoglobin-derived peptide containing three additional amino acids, is a CB1 cannabinoid receptor agonist. RVD-Hpα is a positive allosteric modulator of cannabinoid receptor 2 .

HY-P1091A

Hemopressin(human, mouse) TFA	Cannabinoid Receptor	Neurological Disease
Hemopressin TFA is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin TFA is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin TFA exerts antinociceptive action in inflammatory pain models .

HY-P1090A

Hemopressin(rat) TFA	Cannabinoid Receptor	Neurological Disease
Hemopressin(rat) TFA is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin(rat) TFA is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin(rat) TFA exerts antinociceptive action in inflammatory pain models .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-153169

6PPD-Q 5+ Cited Publications 6PPD-Quinone	Quinones Structural Classification Alkaloids Classification of Application Fields Other Alkaloids Other Diseases Benzene Quinones Endogenous metabolite Disease Research Fields Source Classification	α-synuclein Environmental Pollutants
6PPD-Q (6PPD-Quinone) is an environmental pollutant that can be detected in human urine and is widely present in the environment. 6PPD-Q targets and binds to CNR2, CNR1, AA2AR, LCAT, and TRPA1, with CNR2 exhibiting the highest binding affinity, potentially acting as a CNR2 receptor agonist to activate cannabinoid receptors. 6PPD-Q induces intestinal inflammation and barrier damage by disrupting mitochondrial function, reducing neuronal glycolysis metabolites and TCA cycle intermediates, and exacerbating α-synuclein (α-syn) aggregation. 6PPD-Q is applicable in research on environmental toxicology, neurodegenerative diseases, and inflammation-related disorders .

HY-110028

Leelamine hydrochloride	other families Classification of Application Fields Pinaceae Terpenoids Diterpenoids Plants Disease Research Fields Pinus massoniana Lamb. Endocrinology Source Classification	Cannabinoid Receptor Fatty Acid Synthase (FASN) Androgen Receptor
Leelamine hydrochloride is a tricyclic diterpene molecule that is extracted from the bark of pine trees . Leelamine hydrochloride is a cannabinoid receptor type 1 (CB1) agonist and a inhibitor of SREBP1-regulated fatty acid/lipid synthesis in prostate cancer cells that is not affected by androgen receptor status. Leelamine hydrochloride suppresses transcriptional activity of androgen receptor, which is known to regulate fatty acid synthesis ^[2,3].

HY-113070

Dihomo-γ-Linolenoyl Ethanolamide	Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Endogenous metabolite Disease Research Fields Source Classification	Cannabinoid Receptor Endogenous Metabolite
Dihomo-γ-Linolenoyl Ethanolamide, an endocannabinoid, is a cannabinoid (CB) receptor agonist with K_is of 857 nM and 598 nM for human recombinant CB1 and CB2 receptors, respectively .

HY-W013788

2-Palmitoylglycerol 2-Palm-Gl	Natural Products Microorganisms Endogenous metabolite Source Classification	Cannabinoid Receptor
2-Palmitoylglycerol (2-Palm-Gl), an congener of 2-arachidonoylglycerol (2-AG), is a modest cannabinoid receptor CB1 agonist. 2-Palmitoylglycerol also may be an endogenous ligand for GPR119 .

HY-110016

Docosatetraenylethanolamide DEA	Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Endogenous Metabolite Cannabinoid Receptor
Docosatetraenylethanolamide (DEA) is a cannabinoid receptor 1 (CB1) agonist. Docosatetraenylethanolamide inhibits the specific binding of cannabinoid probe to rat synaptosomal membranes with a K_i value of 34.4 nM. Docosatetraenylethanolamide can be used in the research of nervous system .

HY-134615

Mead ethanolamide	Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Endogenous metabolite Disease Research Fields Source Classification	Cannabinoid Receptor Endogenous Metabolite
Mead ethanolamide is an endogenous **cannabinoid receptor** agonist with K_d values of 753 nM and 1810 nM against CB1 and CB2, respectively .

HY-135882

OMDM-6	Alkaloids Monophenols Neurological Disease Classification of Application Fields Other Alkaloids Phenols Endogenous metabolite Disease Research Fields Source Classification	TRP Channel Cannabinoid Receptor Endogenous Metabolite
OMDM-6 is a hybrid agonist of *vanilloid receptor* type 1 (VR1, TRPV1) (EC₅₀*=75 nM) and cannabinoid* receptor type 1 (CB1) (K_i=3.2 μM). OMDM-6 inhibits anandamide cellular uptake (ACU) with a K_i of 7.0 μM .

HY-135881

OMDM-5	Alkaloids Monophenols Neurological Disease Classification of Application Fields Other Alkaloids Phenols Endogenous metabolite Disease Research Fields Source Classification	TRP Channel Endogenous Metabolite
OMDM-5 is a selective inhibitor of anandamide cellular uptake (ACU), with a K_i of 4.8 μM. OMDM-5 is also a potent *vanilloid receptor* type 1 (VR1, TRPV1)** agonist, with an EC₅₀ of 75 nM, and shows weakly active as cannabinoid receptor type 1 (CB1) ligand (K_i=4.9 μM) .

HY-W013788R

2-Palmitoylglycerol (Standard) 2-Palm-Gl (Standard)	Structural Classification Natural Products Microorganisms Endogenous metabolite Source Classification	Reference Standards Cannabinoid Receptor
2-Palmitoylglycerol (Standard) is the analytical standard of 2-Palmitoylglycerol. This product is intended for research and analytical applications. 2-Palmitoylglycerol (2-Palm-Gl), an congener of 2-arachidonoylglycerol (2-AG), is a modest cannabinoid receptor CB1 agonist. 2-Palmitoylglycerol also may be an endogenous ligand for GPR119 .

Cat. No.	Product Name	Chemical Structure

HY-124089S

Eicosapentaenoyl ethanolamide-d4

Eicosapentaenoyl ethanolamide-d₄ is the deuterium labeled Eicosapentaenoyl ethanolamide. Eicosapentaenoyl ethanolamide, an omega-3 fatty acid, is one of N-acylethanolamines (NAEs). Eicosapentaenoyl ethanolamide is cannabinoid CB1/CB2 receptor agonist. Eicosapentaenoyl ethanolamide acts as a metabolic signal. Eicosapentaenoyl ethanolamide inhibits dietary restriction (DR)-induced lifespan extension in wild type animals and suppresses lifespan extension in a TOR pathway mutant .

HY-W770198

2-Linoleoyl glycerol-d5

2-Linoleoyl glycerol-d₅ (2-Monolinolein-d₅; 2-Monolinoleoylglycerol-d₅) is the deuterium labeled 2-Linoleoyl glycerol (HY-130311). 2-Linoleoyl glycerol (2-Monolinolein; 2-Monolinoleoylglycerol) is a monoacylglycerol that is an antagonist and partial agonist at the type 1 cannabinoid CB1 receptor. The potency of 2-Linoleoyl glycerol can be enhanced by JZL195 (HY-15250), an inhibitor of FAAH and MAGL, and inhibited by the CB1 antagonist AM251 (HY-15443) and Cannabidiol. As a CB1 antagonist, 2-Linoleoyl glycerol does not enhance, but only attenuates, the activity of the CB1/CB2 receptor ligands cannabinoids (AEA) and 2-arachidonoylglycerol (2-AG) .

Cat. No.	Product Name		Classification

HY-155481

CB2 receptor antagonist 3		Azide
CB2 receptor antagonist 3 (compound (S)-1) is an inverse agonist of the cannabinoid receptor CB2R with Kd=39 nM. CB2 receptor antagonist 3 can be used as a tool to synthesize a variety of CB2R probes .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks